AU2015226100B2 - Multimeric Fc proteins - Google Patents

Multimeric Fc proteins Download PDF

Info

Publication number
AU2015226100B2
AU2015226100B2 AU2015226100A AU2015226100A AU2015226100B2 AU 2015226100 B2 AU2015226100 B2 AU 2015226100B2 AU 2015226100 A AU2015226100 A AU 2015226100A AU 2015226100 A AU2015226100 A AU 2015226100A AU 2015226100 B2 AU2015226100 B2 AU 2015226100B2
Authority
AU
Australia
Prior art keywords
residue
lgg4
fusion protein
substituted
multimeric fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015226100A
Other languages
English (en)
Other versions
AU2015226100A1 (en
Inventor
Farnaz FALLAH-ARANI
Robert Anthony Griffin
David Paul Humphreys
Shirley Jane Peters
Bryan John Smith
Paul Edward Stephens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Biopharma SRL
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201403912A external-priority patent/GB201403912D0/en
Priority claimed from GB201403913A external-priority patent/GB201403913D0/en
Priority claimed from GB201405952A external-priority patent/GB201405952D0/en
Priority claimed from GB201412646A external-priority patent/GB201412646D0/en
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of AU2015226100A1 publication Critical patent/AU2015226100A1/en
Application granted granted Critical
Publication of AU2015226100B2 publication Critical patent/AU2015226100B2/en
Assigned to UCB Biopharma SRL reassignment UCB Biopharma SRL Amend patent request/document other than specification (104) Assignors: UCB BIOPHARMA SPRL
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/528—CH4 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
AU2015226100A 2014-03-05 2015-03-05 Multimeric Fc proteins Ceased AU2015226100B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB1403912.7 2014-03-05
GB201403912A GB201403912D0 (en) 2014-03-05 2014-03-05 Proteins
GB201403913A GB201403913D0 (en) 2014-03-05 2014-03-05 Proteins
GB1403913.5 2014-03-05
GB201405952A GB201405952D0 (en) 2014-04-02 2014-04-02 Proteins
GB1405952.1 2014-04-02
GB201412646A GB201412646D0 (en) 2014-07-16 2014-07-16 Proteins
GB1412646.0 2014-07-16
PCT/EP2015/054687 WO2015132364A1 (en) 2014-03-05 2015-03-05 Multimeric fc proteins

Publications (2)

Publication Number Publication Date
AU2015226100A1 AU2015226100A1 (en) 2016-08-25
AU2015226100B2 true AU2015226100B2 (en) 2020-05-07

Family

ID=52629578

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015226100A Ceased AU2015226100B2 (en) 2014-03-05 2015-03-05 Multimeric Fc proteins

Country Status (15)

Country Link
US (1) US11352414B2 (https=)
EP (1) EP3114143B1 (https=)
JP (1) JP6851200B2 (https=)
KR (1) KR20160130463A (https=)
CN (1) CN106068274A (https=)
AU (1) AU2015226100B2 (https=)
BR (1) BR112016020368A2 (https=)
CA (1) CA2939198A1 (https=)
IL (1) IL247096A0 (https=)
MX (1) MX2016010951A (https=)
RU (1) RU2016139006A (https=)
SG (1) SG11201606597QA (https=)
TW (1) TW201619188A (https=)
UY (1) UY36021A (https=)
WO (1) WO2015132364A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016010951A (es) 2014-03-05 2016-11-29 Ucb Biopharma Sprl Proteinas de fc multimericas.
EP4299595A3 (en) 2014-05-02 2024-03-13 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs
ES2784603T3 (es) 2015-06-02 2020-09-29 Novo Nordisk As Insulinas con extensiones recombinantes polares
GB201511787D0 (en) * 2015-07-06 2015-08-19 Ucb Biopharma Sprl Proteins
GB201513033D0 (en) * 2015-07-23 2015-09-09 Ucb Biopharma Sprl Proteins
KR20250053203A (ko) 2015-07-24 2025-04-21 글리크닉 인코포레이티드 향상된 상보체 결합을 갖는 규칙적으로 다형체화된 면역글로불린 fc 조성물을 생성하기 위한 인간 단백질 단편의 융합 단백질
EP3355931B1 (en) 2015-10-01 2024-06-26 Novo Nordisk A/S Protein conjugates
AU2017213117A1 (en) * 2016-01-27 2018-07-19 CSL Behring Lengnau AG Recombinant IgG Fc multimers
EP3423572B1 (en) 2016-03-02 2023-11-29 Momenta Pharmaceuticals, Inc. Methods related to engineered fc constructs
GB201607979D0 (en) * 2016-05-06 2016-06-22 Liverpool School Tropical Medicine Monomeric proteins and uses thereof
DK3484514T3 (da) 2016-05-23 2024-01-29 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
AU2017279538A1 (en) 2016-06-07 2019-01-03 Gliknik Inc. Cysteine-optimized stradomers
AU2017300794A1 (en) 2016-07-22 2019-01-24 Gliknik Inc. Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced fc receptor binding
MX2019006573A (es) 2016-12-09 2019-11-18 Gliknik Inc Optimizacion de fabricacion de gl-2045 un stradomer multimerizante.
CN110022898B (zh) 2016-12-09 2023-07-04 格利克尼克股份有限公司 用多价Fc化合物治疗炎性疾病的方法
JP7146771B2 (ja) 2017-01-06 2022-10-04 モメンタ ファーマシューティカルズ インコーポレイテッド 操作されたＦｃコンストラクトに関する組成物及び方法
CN113603780B (zh) * 2017-03-28 2022-07-01 礼进生物医药科技（上海）有限公司 用于增强肿瘤微环境中免疫应答的治疗剂和方法
JP2020513019A (ja) 2017-04-05 2020-04-30 ノヴォ ノルディスク アー／エス オリゴマー伸長インスリン−Ｆｃコンジュゲート
KR101913743B1 (ko) 2017-04-07 2018-11-01 국민대학교 산학협력단 혈중 반감기 연장을 위한 항체 Fc 변이체들
KR20200014379A (ko) * 2017-06-05 2020-02-10 얀센 바이오테크 인코포레이티드 비대칭 ch2-ch3 영역 돌연변이를 갖는 조작된 다중특이성 항체 및 다른 다량체 단백질
US20210095006A1 (en) 2017-12-14 2021-04-01 CSL Behring Lengnau AG RECOMBINANT IgG Fc MULTIMERS FOR THE TREATMENT OF NEUROMYELITIS OPTICA
CN112236449A (zh) * 2018-03-16 2021-01-15 利物浦热带医学院 嵌合fc受体结合蛋白及其用途
KR102232659B1 (ko) * 2018-07-16 2021-03-26 전북대학교 산학협력단 항원전달용 폴리펩타이드, 이를 포함하는 Fc-융합 단백질 및 이의 용도
WO2020102251A1 (en) 2018-11-14 2020-05-22 Jn Biosciences Llc Multimeric hybrid fc proteins for replacement of ivig
AU2020344164A1 (en) 2019-09-13 2022-04-14 CSL Behring Lengnau AG Recombinant IgG Fc multimers for the treatment of immune complex-mediated kidney disorders
BR112022010096A2 (pt) * 2019-12-06 2022-09-06 CSL Behring Lengnau AG Composições estáveis de multímeros fc
GB2595299B (en) * 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions
CN115724985A (zh) * 2021-08-27 2023-03-03 三生国健药业（上海）股份有限公司 一种cdc平台抗体
EP4536276A1 (en) * 2022-06-10 2025-04-16 Research Development Foundation Engineered fcriib selective igg1 fc variants and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020147326A1 (en) * 1996-06-14 2002-10-10 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
WO2008151088A2 (en) * 2007-06-01 2008-12-11 University Of Maryland, Baltimore Immunoglobulin constant region fc receptor binding agents
WO2011073692A1 (en) * 2009-12-18 2011-06-23 The University Of Nottingham Proteins, nucleic acid molecules and compositions
WO2013049254A1 (en) * 2011-09-26 2013-04-04 Jn Biosciences Llc Hybrid constant regions
WO2014022592A1 (en) * 2012-08-02 2014-02-06 Jn Biosciences Llc Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6114515A (en) 1997-08-25 2000-09-05 Smithkline Beecham Corporation PIGRL-1, a member of immunoglobulin gene superfamily
GB9720054D0 (en) 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
US6284536B1 (en) 1998-04-20 2001-09-04 The Regents Of The University Of California Modified immunoglobin molecules and methods for use thereof
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
MY129566A (en) 1999-01-19 2007-04-30 Nestle Sa A hypoallergenic composition containing tolerogenic peptides inducing oral tolerance
US6475749B1 (en) 1999-08-11 2002-11-05 The Regents Of The University Of California Rh hybrid antibody
DE10001372A1 (de) 2000-01-14 2001-08-02 Deutsches Krebsforsch Anti-CD3-Einzelketten-Antikörper mit humanem Cmu3- und Cmu4- Domänen
RU2003129528A (ru) 2001-03-07 2005-04-10 Мерк Патент ГмбХ (DE) Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP1553975B8 (en) 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
US8388955B2 (en) * 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
ES2551439T5 (es) 2003-07-01 2018-11-08 Ucb Biopharma Sprl Fragmentos Fab de anticuerpos modificados
US20060134105A1 (en) 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
EP2471813B1 (en) 2004-07-15 2014-12-31 Xencor, Inc. Optimized Fc variants
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
WO2008032833A1 (en) 2006-09-14 2008-03-20 Medical & Biological Laboratories Co., Ltd. Antibody having enhanced adcc activity and method for production thereof
EP2158318A2 (en) 2007-05-14 2010-03-03 Biogen Idec MA, Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
EP2260057B1 (en) * 2008-03-13 2016-11-23 Biotest AG Anti-CD4 antibody dosage regimen for treating autoimmune disease
JP2012515556A (ja) * 2009-01-23 2012-07-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法
CN102781963B (zh) 2009-10-27 2018-02-16 Ucb医药有限公司 功能修饰性NAv1.7抗体
TWI542597B (zh) 2010-07-28 2016-07-21 吉林尼克公司 產生依序多聚體化免疫球蛋白ｆｃ組合物之天然人類蛋白質片段之融合蛋白
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
JP6313712B2 (ja) 2011-12-21 2018-04-18 アムジエン・インコーポレーテツド 新生児Ｆｃ受容体への結合を強化された変異型Ｆｃポリペプチド
KR102041412B1 (ko) 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
CN104736174B (zh) 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
KR20150037959A (ko) 2012-08-02 2015-04-08 에프. 호프만-라 로슈 아게 단량체 및 다량체 분자의 제조 방법 및 이의 용도
US9683044B2 (en) 2012-08-20 2017-06-20 Gliknik Inc. Molecules with antigen binding and polyvalent FC gamma receptor binding activity
BR112015008663B1 (pt) 2012-10-17 2021-01-12 CSL Behring Lengnau AG Uso de uma quantidade eficaz de uma proteína polimérica compreendendo seis unidades demonômero de polipeptídeo
MX2016010951A (es) * 2014-03-05 2016-11-29 Ucb Biopharma Sprl Proteinas de fc multimericas.
CA2939201A1 (en) 2014-03-05 2015-09-11 Ucb Biopharma Sprl Multimeric fc proteins
CA2945882A1 (en) 2014-04-16 2015-10-22 Ucb Biopharma Sprl Multimeric fc proteins
EP4299595A3 (en) 2014-05-02 2024-03-13 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs
AU2016227632A1 (en) 2015-03-05 2017-09-14 Ucb Biopharma Sprl Polymeric Fc proteins and methods of screening to alter their functional characteristics
GB201511787D0 (en) 2015-07-06 2015-08-19 Ucb Biopharma Sprl Proteins

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020147326A1 (en) * 1996-06-14 2002-10-10 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
WO2008151088A2 (en) * 2007-06-01 2008-12-11 University Of Maryland, Baltimore Immunoglobulin constant region fc receptor binding agents
WO2011073692A1 (en) * 2009-12-18 2011-06-23 The University Of Nottingham Proteins, nucleic acid molecules and compositions
WO2013049254A1 (en) * 2011-09-26 2013-04-04 Jn Biosciences Llc Hybrid constant regions
WO2014022592A1 (en) * 2012-08-02 2014-02-06 Jn Biosciences Llc Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Anonymous: lgG-Fc Engineering For Therapeutic Use, lnvivoGen Insight, lnvivoGen, 1 May 2006, pages 1-4Retrieved from the Internet: URL:http://www.invivogen.com/docs/lnsight200605.pdf *
MEKHAIEL, David N. A. et al., Polymeric human Fe-fusion proteins with modified effector functions. SCIENTIFIC REPORTS, vol. 1, 19 October 2011 *
SMITH, R I et al., Addition of a mu-tailpiece to lgG results in polymeric antibodies with enhanced effector functions including complement-mediated cytolysis by lgG4. THE JOURNAL OF IMMUNOLOGY, vol. 154, no. 5, 1 March 1995, pages 2226-2236 *
SORENSEN, V et al., Effect of the lgM and lgA secretory tailpieces on polymerization and secretion of lgM and lgG. THE JOURNAL OF IMMUNOLOGY, vol. 156, no. 8, 15 April 1996, pages 2858-2865 *
SORENSEN, Vigdis et al., Structural requirements for incorporation of J chain into human lgM and lgA. INTERNATIONAL IMMUNOLOGY, vol. 12, no. 1, 1 January 2000, pages 19-27 *
YOO, Esther M et al., Structural Requirements for Polymeric lmmunoglobulin Assembly and Association with J Chain. JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 47, 19 November 1999, pages 33771-33777 *

Also Published As

Publication number Publication date
WO2015132364A1 (en) 2015-09-11
CN106068274A (zh) 2016-11-02
UY36021A (es) 2015-09-30
BR112016020368A2 (pt) 2018-01-23
EP3114143A1 (en) 2017-01-11
SG11201606597QA (en) 2016-09-29
RU2016139006A (ru) 2018-04-05
MX2016010951A (es) 2016-11-29
AU2015226100A1 (en) 2016-08-25
EP3114143B1 (en) 2020-07-08
JP2017512063A (ja) 2017-05-18
IL247096A0 (en) 2016-09-29
JP6851200B2 (ja) 2021-03-31
KR20160130463A (ko) 2016-11-11
CA2939198A1 (en) 2015-09-11
TW201619188A (zh) 2016-06-01
US20170088603A1 (en) 2017-03-30
US11352414B2 (en) 2022-06-07

Similar Documents

Publication Publication Date Title
AU2015226100B2 (en) Multimeric Fc proteins
AU2015226101B2 (en) Multimeric Fc proteins
US20180044416A1 (en) Polymeric Fc proteins and methods of screening to alter their functional characteristics
JP7797198B2 (ja) ヒトｐｄ－１に対する二機能性分子
US20170029505A1 (en) Multimeric fc proteins
CA3106046A1 (en) Antibody molecules that bind pd-l1 and cd137
WO2017036905A1 (en) Multimeric proteins which bind to human fc-receptors
CN108135976A (zh) 靶向il-23a和b细胞激活因子(baff)的化合物和其用途
CN108473571A (zh) 结合人Fc受体的融合蛋白
WO2020165374A1 (en) Bifunctional molecule comprising il-15ra
US20260049141A1 (en) Multifunctional molecule directed against cd28

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: UCB BIOPHARMA SRL

Free format text: FORMER NAME(S): UCB BIOPHARMA SPRL

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired